Anlotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis

被引：0
|
作者：
Lei, T. [1 ]
Xu, T. [2 ]
Zhang, N. [1 ]
Zou, X. [1 ]
Wei, C. [1 ]
Wang, Z. [1 ]
机构：
[1] Nanjing Med Univ, Affiliated Hosp 2, Nanjing, Peoples R China
[2] Nanjing Med Univ, Nanjing Hosp 1, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Anlotinib; Osimertinib resistance; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-70
引用
收藏
页码：S670 / S670
页数：1
相关论文
共 34 条
  • [31] Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
    Horinouchi, H.
    Goldman, J. W.
    Cho, B. C.
    Tomasini, P.
    Dunbar, M.
    Hoffman, D.
    Parikh, A.
    Blot, V.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 : S1592 - S1592
  • [32] Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
    Horinouchi, H.
    Cho, B. C.
    Camidge, D. R.
    Goto, K.
    Tomasini, P.
    Li, Y.
    Vasilopoulos, A.
    Brunsdon, P.
    Hoffman, D.
    Shi, W.
    Blot, V.
    Goldman, J. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1670 - S1670
  • [33] Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
    Goldman, Jonathan W.
    Horinouchi, Hidehito
    Cho, Byoung Chul
    Tomasini, Pascale
    Dunbar, Martin
    Hoffman, David
    Parikh, Apurvasena
    Blot, Vincent
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Osimertinib combined with dalpiciclib in EGFR-mutant, CDK4/6 pathway-altered, advanced NSCLC patients with acquired resistance to third-generation EGFR-TKIs: A phase II, prospective, multicenter, single-arm clinical trial
    Jiang, X.
    Li, M.
    Jiang, R.
    Huang, C.
    Huang, D.
    Chen, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S874 - S874
1234